Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)

Similar Items

• Haemodynamic effects of riociguat in inoperable/recurrent chronic thromboembolic pulmonary hypertension
  od: Kim, Nick H, i dr.
  Izdano: (2017)
• Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
  od: Benza, Raymond L., i dr.
  Izdano: (2020)
• Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study)
  od: Marra, Alberto M., i dr.
  Izdano: (2018)
• Effects of riociguat in severe experimental pulmonary hypertension
  od: Kojonazarov, Baktybek, i dr.
  Izdano: (2011)
• Treatment pathways in Finnish patients with pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH)
  od: Markku Pentikäinen, i dr.
  Izdano: (2025-01-01)